Slingshot members are tracking this event:
Lilly's Taltz (ixekizumab) Receives U.S. FDA Approval for the Treatment of Moderate-to-Severe Plaque Psoriasis
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
|LLY||Community voting in process|
Slingshot Insights Explained
Mar 22, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Moderate-to-severe Plaque Psoriasis, Ixekizumab, Talz